In a recent study, Monash University and Lava Therapeutics collaborated to detail a new immuno-oncology method that can be used for potential cancer treatments. The authors of this joint study are Dr. Roeland Lameris from UMC in Amsterdam and others.

The research was published in the journal Nature Cancer and was co-led by Professor Jamie Rossjohn and Dr. Adam Shahine, an ARC award-winning researcher at the Monash Institute for Biomedical Discovery, and emphasized the synergy between antibody fragments (called nanobodies) This fragment not only serves to help connect two key immune cell receptors together, but also uses their interaction to enhance the body’s immune response to cancer.

These antibody fragments (called nanobodies) target the interaction between a molecule called CD1d and natural killer T cells (NKT) in a stable and durable manner to combat patients with multiple myeloma and acute myeloid leukemia Of tumor samples.

   These new discoveries will provide a model for potentially new and effective treatments for various cancers.

  The Monash University team used the Australian synchrotron to provide detailed resolution-derived structures to understand how nanobodies act on immune cells in cancer models. Professor Rossjohn said: "We can accurately visualize how Nanobodies recognize CD1d and NKT TCR at the same time, thus providing a molecular basis for their anti-tumor properties."

Hans van der Vliet, Chief Scientific Officer of Lava Therapeutics, said: “By targeting and enhancing human innate natural immune cells (such as NKT cells and γ-δT cells), the therapeutic effect can be enhanced. We believe that our method can eventually be transformed into a wide range of It is applicable to immunotherapy for multiple cancer indications."

Co-first author Dr. Shahine said: "This collaborative work paves the way for the rational development of improved treatments for multiple cancers."